
Infinity Pharmaceuticals INFI
Quarterly report 2023-Q2
added 08-10-2023
Infinity Pharmaceuticals DPO Ratio 2011-2026 | INFI
Annual DPO Ratio Infinity Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.05 K | 81 | 6.33 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.33 K | 81 | 2.49 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amgen
AMGN
|
64.8 | $ 350.13 | 2.98 % | $ 188 B | ||
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Amneal Pharmaceuticals
AMRX
|
21.1 | $ 12.73 | 3.33 % | $ 3.99 B | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.48 | 8.82 % | $ 394 M | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 24.57 | 5.59 % | $ 3.13 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
186 | $ 2.68 | 4.28 % | $ 16.8 M | ||
|
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
Cerus Corporation
CERS
|
242 | $ 1.93 | 4.62 % | $ 368 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
CTI BioPharma Corp.
CTIC
|
306 | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.2 K | - | - | $ 2.18 B | ||
|
Dynavax Technologies Corporation
DVAX
|
52.8 | - | - | $ 2.02 B | ||
|
Coherus BioSciences
CHRS
|
507 | $ 1.73 | 3.59 % | $ 203 M |